Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlphaBreak: FPI-2265 in PSMA-Positive mCRPC
NCT06402331Phase 2Active, not recruiting
- Sponsor
- Fusion Pharmaceuticals Inc.
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of actinium-225 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Fusion Pharmaceuticals Inc.. Started Mar 2024; status: active, not recruiting.
02
Drugs
actinium-225 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06402331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402331.